Nephrotic Syndrome Diagnostics & Therapeutics Market Demand Analysis, Growth, Trends and Forecast - 2031

The global nephrotic syndrome diagnostics & therapeutics market is anticipated to grow at a CAGR of around 5.6% during the forecast period (2024-2031). The key factor to drive the market growth includesthe increasing prevalence of diabetes that results in increased chances of nephrotic syndrome. For instance, In the European Union, approximately 32.3 million adults were diagnosed with diabetes in 2019, up from an estimated 16.8 million adults in 2000. In 2019, it was estimated that around 24.2 million people in Europe will be having diabetes but will go undiagnosed.Since 2000, the number of men diagnosed with diabetes has more than doubled, rising from about 7.3 million in 2000 to 16.7 million in 2019. Women with diabetes have also increased significantly, from 9.5 million in 2000 to 15.6 million in 2019.

Get Free Sample link @ https://www.omrglobal.com/request-sample/nephrotic-syndrome-diagnostics-therapeutics-market

Rising acquisitions, product approval, collaborations among the major players in the market also propel the growth of the market. For instance, in April 2019, Angion announced a partnership agreement with Nephrotic Syndrome Study Network (NEPTUNE)in order to investigate ANG-3070. This clinical research is based on understanding and treatment of kidney disorders.These findings of the research will supportdetermining the inclusion requirements for a biomarker stratified prospective clinical trial evaluating the safety and efficacy of ANG-3070 in primary Focal segmental glomerulosclerosis (FSGS) patients, ensuring that the most likely patients benefit from treatment.

Full report of Nephrotic Syndrome Diagnostics & Therapeutics Market available @ https://www.omrglobal.com/industry-reports/nephrotic-syndrome-diagnostics-therapeutics-market

Market Coverage

Segment Covered-
o By Diagnosis Test

o By Treatment

Regions Covered-
o North America

o Europe

o Asia-Pacific

o Rest of the World

Competitive Landscape-
Key questions addressed by the report

What is the market growth rate?
Which segment and region dominate the market in the base year?
Which segment and region will project the fastest growth in the market?
How COVID-19 impacted the market?
o Deviation from the pre-COVID-19 forecast

o Most affected region and segment

Who is the leader in the market?
How players are addressing challenges to sustain growth?
Where is the investment opportunity?
Global Nephrotic Syndrome Diagnostics & Therapeutics Market Report Segment

By Diagnosis Tests

Urinalysis
Blood Tests
Kidney Biopsy
Others (CT Scan, Renal Ultra-Sonography)
By Treatment

Blood Pressure Lowering Medications
o Angiotensin-Converting Enzyme (ACE) Inhibitors

o Angiotensin Receptor Blockers (ARBs)

o Others (Renin Inhibitors and Benazepril)

Immune System-Suppressing Medications
Cholesterol-Reducing Medications
Others (Blood Thinners)


Reasons to Buying From us -

1. We cover more than 15 major industries, further segmented into more than 90 sectors.
2. More than 120 countries are for analysis.
3. Over 100+ paid data sources mined for investigation.
4. Our expert research analysts answer all your questions before and after purchasing your report.


For More Customized Data, Request for Report Customization @ https://www.omrglobal.com/report-customization/nephrotic-syndrome-diagnostics-therapeutics-market

Media Contact:

Contact Person: Mr. Anurag Tiwari
Email: anurag@omrglobal.com
Contact no: +91 780-304-0404
Company Name: Orion Market Research

About Orion Market Research

Orion Market Research (OMR) is a market research and consulting company known for its crisp and concise reports. The company is equipped with an experienced team of analysts and consultants. OMR offers quality syndicated research reports, customized research reports, consulting and other research-based services. The company also offers Digital Marketing services through its subsidiary OMR Digital and Software development and Consulting Services through another subsidiary Encanto Technologies.

This release was published on openPR.